Picard Medical, Inc. PMI
Picard Medical, Inc. (NYSE: PMI) is a cardio-renal-metabolic medical device company. Its next catalyst on record is Unicorn driver: Complete regulatory testing (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Unicorn driver — Complete regulatory testing (H2 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SynCardia TAH (PMA-approved BTT) | Bridge to transplant | — | NA_NON_THERAPEUTIC |
| Freedom+ portable driver (PMA supplements under FDA review) | — | — | NA_NON_THERAPEUTIC |
| Unicorn driver system | — | — | NA_NON_THERAPEUTIC |
| Emperor TAH (fully implantable) | End-stage heart failure | — | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.